Eventide Asset Management, LLC is a Boston-based investment adviser practicing "investing that makes the world rejoice®." Founded in 2008, Eventide's vision is to serve individuals, financial advisors, and institutions by providing high-performance investments that we believe create compelling value for the global common good.

Eventide was named one of Pensions & Investments’ Best Places to Work in Money Management 2022.

For more information on the award methodology please visit: https://www.pionline.com/best-places-to-work/2022

For our Social Media Terms of Use and additional disclosures, please visit:
https://www.eventideinvestments.com/social-media-guidelines/

Zentalis Pharmaceuticals

Talaris Therapeutics

Karuna Therapeutics

Annexon Biosciences

Magenta Therapeutics

Collegium Pharmaceutical

Cullinan Oncology

Dice Therapeutics

Roivant Sciences

Pliant Therapeutics

Praxis Precision Medicines

Freeline

Prometheus Biosciences

Eventide Asset Management

We are hiring! 

Eventide Asset Management is hiring a Head of Marketing & Communications and a Director of Digital Marketing. These roles will be a driving force in our journey towards principled, faith-driven investing!  As a key member of the CEO's executive team, the Head of Marketing and Communications will spearhead the development of a marketing-centric organizational culture and will be essential in leading us toward excellence. The Director of Digital Marketing will lead a digital transformation agenda that amplifies Eventide's brand experience.

We are looking for leaders with excellence and a passion for Eventide's mission. Eventide employees work hard for the sake of others—our clients, our colleagues, and our world. Our mission is to honor God and serve our clients through investments that make the world rejoice.

Read more about these careers here: https://lnkd.in/dsPS3y79

If you are interested, please send your CV and cover letter to careers@eventideinvestments.com, and a member of our Human Resources department will be in touch with you!

Join us at 3pm ET this afternoon to hear from Dr. Finny Kuruvilla in our quarterly CIO Update.

This webinar will be a 2024 macro look ahead that shares our "three legs of the stool" approach to evaluating the health of the markets–considering leading economic indicators, valuation, and sentiment.

We are excited to see you there! 

Register here: https://lnkd.in/gm2cB4uk

"We are closer than ever to a more amenable environment for biotech,” shared Eventide’s Kyle R. with Investor's Business Daily in today’s feature about 2024 biotech expectations. 

In this article, Kyle R. shares Eventide’s optimism of enhancing the quality of life for individuals and communities through the developments emerging in the biotech industry. 

Read more here: https://lnkd.in/gHxzNdHN

#PharmaIndustry #Biotech2024 #Alzheimers

Join us next week on Thursday, January 18th, at 3pm ET to hear from Dr. Finny Kuruvilla in our quarterly CIO Update.

This webinar shares our "three legs of the stool" approach to evaluating the health of the markets–considering leading economic indicators, valuation, and sentiment. 

We hope to see you there!

Some investment strategies are active, while others are passive. Investors using the more active approaches often strategize to pursue higher returns than the rest of the market—a concept referred to as “alpha.” Check out this recent episode on Faith and Finance Live, where host Rob West and Shaun Morgan from Eventide discuss a fourth source of alpha that Christian investors may want to consider.

Morningstar recently highlighted Eventide as a “fast-growing firm” in its feature on faith-based investing. Our CEO, Robin Cheriakalath John, underscored Eventide’s dual mandate of seeking performance and a better world. Robin explained, “We believe companies that serve stakeholders well will ultimately do better in the long term. That’s good news for all investors regardless of your background.”

Read the piece here: https://lnkd.in/gpU36hHe

#valuesbasedinvesting #Christianfinance

Newsweek recently published an article by Eventide Asset Management’s Kyle Rasbach about emerging new therapies for brain disorders like schizophrenia. After decades of stagnation, the industry is finally seeing innovative treatment options develop that could genuinely transform outcomes for patients and society. 

As investors, we are currently in a unique time where we can come together to advance human flourishing by funding innovation in #biotech while also generating long-term financial returns. 

Read Kyle’s entire piece here: https://lnkd.in/eJYsRGQn

#healthcareinnovation #pharma #pharmaceuticals #mentalhealth #brainhealth #medicine #investing

Eventide is happy to be a local host of the 2024 Faith Driven Investor  Conference Watch Party: Build. Give. Invest. The event will be held on January 24th at our headquarters in Boston. For more information and to register, please visit https://lnkd.in/gNvvhtVW.

To register for a watch party near you, visit https://lnkd.in/gS5pt7xa.

Eventide's Kyle Rasbach spoke with Investor's Business Daily about the breakthroughs in treating Alzheimer's.

Kyle discusses how the future of Alzheimer's treatments relies on creating powerful drugs that can decrease beta-amyloid—an amino acid present in the brains of Alzheimer's patients—without causing as much brain swelling.

Scientists have already made promising strides in preventing the deterioration of the human brain, and their ongoing efforts will uncover solutions for treating Alzheimer's.

#PharmaIndustry #Biotech #Alzheimers

“I think sometimes people start with profit as a kind of motive–and it’s very easy to get discouraged when it’s all self-centered in that way.”– Eventide Asset Management CEO Robin Cheriakalath John 

Listen to the discussion between Stacy Havener and Robin Cheriakalath John on Billion Dollar Backstory Podcast, as they explore the challenges of launching Eventide with no track record, no assets, but an unwavering belief.

#investing #values #mission

Google Tag Manager

Global Site Tag

DMARC

Google Universal Analytics

Google Apps for Business

GoDaddy DNS

Hubspot Hosted

Fastly Hosted

Fastly Load Balancer

Chief Compliance Officer

Jennifer M. Reiche

Chief Compliance Officer and General Counsel

Peter Luiso

CEO, Co-Founder

Robin Cheriakalath John

Finance and Administration

Abel M. Ballew

Sales and Support

Ally Espinosa, AIF

Ann-Marie Keltner

Marketing and Product

Carly Shotmeyer

Chris Grogan, CFA

Chris Pocsik, CPA

Regional Director

Colby Smidt

Dolores Bamford

Co-Chief Investment Officer and Senior Portfolio Manager

Chief Executive Officer

Kyle Rasbach

Managing Director

Finny Kuruvilla

Chief Investment Officer, Portfolio Manager

Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development.

Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.

Turnstone Biologics is a privately-held clinical stage biotech company.

Roivant Sciences is a biopharmaceutical company focused on the development of medicines and healthcare technologies to patients.

Zentalis is a pharmaceutical company focused on developing clinical therapeutics for cancer patients.

VYNE Therapeutics is a clinical late-stage biopharmaceutical company developing treatments associated with dermatologic conditions.

Annexon Biosciences is a biotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders.

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.

Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.

Private Equity Stage Investors with Investments in Missouri

Venture Stage Investors with Investments in Switzerland

Early Stage Venture Investors with Investments in Dallas, Texas

Venture Stage Investors with Investments in Dallas, Texas

Eventide Asset Management, LLC is a Boston-based investment adviser practicing "investing that makes the world rejoice®."​ Founded in 2008, Eventide's vision is to serve individuals, financial advisors, and institutions by providing high-performance investments that we believe create compelling value for the global common good.

EVENTIDE ASSET MANAGMENT LLC

Boston

Massachusetts

United States

North America

Eventide

Eventide Announces Launch of Eventide High Dividend ETF (NYSE Arca: ELCV)

Eventide Communications Expands Speech Factor AI Suite for Optimized PSAP Performance

Eventide Communications Supports Campus Safety and Security

Eventide Asset Management Announces Final Close of Eventide Healthcare Innovation Fund I, LP

AGENT511 Unveils TEXTBLUE Integration with Eventide for Next-Gen Emergency Communication

United Kingdom

Europe

Pakistan

Asia

HTML5

Lead Flows

HubSpot Marketing Hub

jQuery

F5 NGINX

Wordpress

Adobe Fonts

Office 365

Google Maps API

Google Drive

Westfield Capital Management Company is an asset management firm that offers investment strategies focused on creating value for shareholders.

Westfield Capital Management Company

Sensible Financial Planning is a financial planning firm that provides investment and financial planning services with a focus on creating value for clients.

Sensible Financial Planning

Launchpad Venture Group is an investment group that focuses on providing capital to innovative businesses with the potential to create value for shareholders.

Launchpad Venture Group

Eventide Investments is a values-driven asset management firm that offers investment strategies that are rooted in the belief that the purpose of business is to serve others. The company integrates financial and values analysis to create portfolios that aim to provide competitive returns while also making a positive impact on the world.

news impact assignment basic	general
public peers	general	May 13, 2024 5:11 PM	49992f3f
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 28, 2024 1:50 PM	e0b56d3b
crunchbase profile	general	Oct 28, 2024 2:44 PM	b194df4e
li profile	general	May 13, 2024 5:11 PM	9f926287
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	8661a5d8
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:EVENTIDEINVESTMENTS

Eventide Investments